Latest Multiple Sclerosis News

Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.

Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.

Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.

Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.

Immutep Limited has successfully completed the single ascending dose phase of its IMP761 trial, showing promising safety and immunosuppressive effects in healthy volunteers. The biotech’s novel LAG-3 agonist could reshape autoimmune disease treatment.

Immutep Limited reports encouraging Phase I results for IMP761, a novel LAG-3 agonist antibody targeting autoimmune diseases, demonstrating dose-dependent immunosuppression and a strong safety profile. Further trial updates are expected in early 2026.

Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.